Last reviewed · How we verify
treatment of TKI in CML
treatment of TKI in CML is a Tyrosine kinase inhibitor Small molecule drug developed by Poitiers University Hospital. It is currently in Phase 3 development for Chronic myeloid leukemia (CML) treatment.
This drug targets the BCR-ABL protein to inhibit cancer cell growth in chronic myeloid leukemia.
This drug targets the BCR-ABL protein to inhibit cancer cell growth in chronic myeloid leukemia. Used for Chronic myeloid leukemia (CML) treatment.
At a glance
| Generic name | treatment of TKI in CML |
|---|---|
| Sponsor | Poitiers University Hospital |
| Drug class | Tyrosine kinase inhibitor |
| Target | BCR-ABL |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BCR-ABL is a fusion protein resulting from a chromosomal abnormality in CML cells. By inhibiting this protein, the drug effectively blocks the proliferation of cancer cells.
Approved indications
- Chronic myeloid leukemia (CML) treatment
Common side effects
- Myelosuppression
- Nausea
- Diarrhea
- Fatigue
- Headache
Key clinical trials
- Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML (PHASE2)
- TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients (PHASE3)
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP (PHASE2)
- Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (PHASE2)
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP (PHASE3)
- A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait
- A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (PHASE3)
- Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- treatment of TKI in CML CI brief — competitive landscape report
- treatment of TKI in CML updates RSS · CI watch RSS
- Poitiers University Hospital portfolio CI
Frequently asked questions about treatment of TKI in CML
What is treatment of TKI in CML?
How does treatment of TKI in CML work?
What is treatment of TKI in CML used for?
Who makes treatment of TKI in CML?
What drug class is treatment of TKI in CML in?
What development phase is treatment of TKI in CML in?
What are the side effects of treatment of TKI in CML?
What does treatment of TKI in CML target?
Related
- Drug class: All Tyrosine kinase inhibitor drugs
- Target: All drugs targeting BCR-ABL
- Manufacturer: Poitiers University Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Chronic myeloid leukemia (CML) treatment
- Compare: treatment of TKI in CML vs similar drugs
- Pricing: treatment of TKI in CML cost, discount & access